Apremilast and Tofacitinib Exert Differential Effects in the Humanized Mouse Model of Alopecia Areata

    June 2019 in “ British Journal of Dermatology ”
    Rimma Laufer Britva, Aviad Keren, Ralf Paus, Amos Gilhar
    Studysummary No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on academic.oup.com →
    Discuss this study in the Community →

    Research cited in this study 8

    1. JAK Inhibitors and Alopecia Areata Lancet · 2019
    2. A Randomized Placebo-Controlled Single-Center Pilot Study of the Safety and Efficacy of Apremilast in Subjects with Moderate-to-Severe Alopecia Areata Archives of dermatological research · 2018
    3. Hair Follicle Immune Privilege Revisited: The Key to Alopecia Areata Management ˜The œjournal of investigative dermatology. Symposium proceedings/˜The œJournal of investigative dermatology symposium proceedings · 2017
    4. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents Journal of Investigative Dermatology Symposium Proceedings · 2017
    5. Lack of Efficacy of Apremilast in 9 Patients with Severe Alopecia Areata Journal of the American Academy of Dermatology · 2017
    6. Alopecia Areata: Animal Models Illuminate Autoimmune Pathogenesis and Novel Immunotherapeutic Strategies Autoimmunity reviews · 2016
    7. The PDE4 Inhibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin In Vivo Journal of Dermatological Science · 2014
    8. Autoimmune Disease Induction in a Healthy Human Organ: A Humanized Mouse Model of Alopecia Areata Journal of Investigative Dermatology · 2012